COMMUNIQUÉS West-GlobeNewswire
-
CoreHealth Announces Leadership Transition as Charles Martin Appointed Chief Executive Officer
23/06/2026 -
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
23/06/2026 -
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
23/06/2026 -
Evaluate Releases Annual World Preview Report Revealing Updated Market Forecasts for the Pharmaceutical Industry
23/06/2026 -
EssilorLuxottica et Meta étendent l’accès à la catégorie des wearables avec une nouvelle collection
23/06/2026 -
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
23/06/2026 -
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
23/06/2026 -
Thousands of Free HIV Tests to Support National HIV Testing Day Activities Across the United States
23/06/2026 -
SK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedside
23/06/2026 -
Ichnos Glenmark Innovation (IGI) Announces Appointment of Mariana Cota Stirner, M.D., Ph.D., as Chief Medical Officer
23/06/2026 -
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advancing Nanoparticle-Encapsulated PNKP Inhibitor in Oncology Space
23/06/2026 -
Berry Street and Tia Partner to Deliver Clinical Nutrition Therapy at Every Stage of a Woman's Life
23/06/2026 -
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
23/06/2026 -
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
23/06/2026 -
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
23/06/2026 -
EssilorLuxottica and Meta expand the accessibility of wearables category with new collection
23/06/2026 -
X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy
23/06/2026 -
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
23/06/2026 -
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
23/06/2026
Pages